Suppression of high lipid diet induced by atherosclerosis sarpogrelate.

Journal of Cellular and Molecular Medicine
Yan-Jun XuNaranjan S Dhalla

Abstract

Sarpogrelate (SP), a serotonin (5-HT2A) receptor antagonist, is used as an anti-platelet agent for the treatment of some vascular diseases. SP has been reported to inhibit 5-HT induced coronary artery spasm, increase in intracellular calcium and smooth muscle cells proliferation. This study was undertaken to test that SP suppresses the development of atherosclerosis due to high cholesterol diet (HCD) by decreasing blood viscosity and oxidative stress. For this purpose, 29 rabbits were divided into four groups: control group (normal diet); normal diet group with SP at the dose of 5 mg/kg/day; HCD group fed 1% cholesterol; and HCD group with SP at the dose of 5 mg/kg/day. After 90 days of the experiment, blood samples were collected and the animals were killed; the thoracic aorta was stained by the Oil Red O staining method. The results indicate that plasma levels of cholesterol, triglycerides and malondialdehyde were increased in rabbits fed HCD. Plasma viscosity and whole blood viscosity were also higher in the HCD group than that in normal diet group. Treatment with SP prevented these alterations induced by HCD whereas this agent had no significant effect in rabbits fed normal diet. Morphological examination of the aorta revea...Continue Reading

References

Dec 23, 1998·Atherosclerosis·R S Rosenson, G D Lowe
Jan 10, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·T BoschW Samtleben
Feb 27, 2003·Journal of Cardiovascular Pharmacology·Yan-Jun XuNaranjan S Dhalla
Jan 14, 2004·Canadian Journal of Physiology and Pharmacology·Harjot K SainiNaranjan S Dhalla
Feb 24, 2004·Cardiovascular Drug Reviews·Harjot K SainiNaranjan S Dhalla
Oct 27, 2004·Pharmacology & Therapeutics·Takafumi NagatomoTadazumi Komiyama
Sep 9, 2006·Pharmacology & Therapeutics·Alberto J Kaumann, Finn Olav Levy
Nov 21, 2007·Expert Opinion on Therapeutic Targets·Todd A DuhamelNaranjan S Dhalla
Apr 18, 2008·Canadian Journal of Physiology and Pharmacology·Santosh K SanganalmathNaranjan S Dhalla
Feb 24, 2009·Journal of Vascular Surgery·Akio KodamaTakeo Itoh
Sep 17, 2009·Current Pharmaceutical Design·A AdameovaN S Dhalla
Nov 4, 2009·International Journal of Cardiology·Yan-Ming SunSheng Bi
Mar 31, 2010·Journal of Cardiovascular Pharmacology·Hongsheng RenXinglei Zhu
Jun 18, 2010·Life Sciences·Mehran HaidariMyron I Cybulsky
Jun 29, 2010·Current Opinion in Lipidology·Anatol Kontush, M John Chapman

❮ Previous
Next ❯

Citations

Feb 26, 2013·Heart Failure Reviews·Yan-Jun XuNaranjan S Dhalla
Mar 27, 2018·Journal of Medical Engineering & Technology·Ashkan JavadzadeganMasud Behnia
Jun 24, 2017·Cardiovascular Therapeutics·Kyung-Yeon Park, Tae-Hwe Heo
Sep 24, 2016·Scientific Reports·José-Ángel García-PedrazaAsunción Morán

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA

Software Mentioned

Anplag

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.